Madrigal Pharmaceuticals

Biotech & Life Sciences · West Conshohocken, United States · Founded 2011 · IPO 2016

Madrigal Pharmaceuticals is a biopharmaceutical company dedicated to developing novel therapeutics for nonalcoholic steatohepatitis (NASH), a severe liver disease. The company operates in the healthcare and pharmaceutical market, focusing on patients with moderate to advanced liver fibrosis (stages F2 to F3) and those with compensated cirrhosis. Madrigal's business model revolves around research and development, clinical trials, and the commercialization of its therapies. The company's first therapy has received accelerated approval from the U.S. Food and Drug Administration (FDA) and is currently undergoing Phase 3 clinical trials. Madrigal generates revenue through the sale of its FDA-approved treatments and potentially through partnerships and licensing agreements. The company's target clients include healthcare providers, hospitals, and patients suffering from NASH. Keywords: biopharmaceutical, NASH, liver disease, therapeutics, FDA-approved, clinical trials, fibrosis, cirrhosis, healthcare, pharmaceutical.

Valuation $10B

Revenue $1.52B

Total funding $50–100M

Power Law Decacorn$10B+ valuation tier Thoroughbred$100M+ revenue

Investors

3 investors on Madrigal Pharmaceuticals's cap table

Sourced from Dealroom's funding history.

Series A 1 investor entered at this stage

Bay City Capital

Series B+ 2 investors entered at this stage

Hercules Capital

Blue Owl Capital

Global footprint

Where Madrigal Pharmaceuticals has talent and traffic

Workforce by country

10 countries with
team presence

🇺🇸 United States88.3%

🇩🇪 Germany4.1%

🇨🇭 Switzerland3.8%

🇫🇷 France0.7%

🇬🇧 United Kingdom0.7%

Top 5 of 10 shown

Web traffic by country

110K monthly visits
across markets

🇺🇸 United States114.9%

🇬🇧 United Kingdom2.1%

🇨🇦 Canada1.8%

🇮🇳 India1.7%

🇯🇵 Japan1.1%

Top 5 markets shown

Talent graph

The shape of Madrigal Pharmaceuticals's talent

Dealroom maps Madrigal Pharmaceuticals's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

10 standout operatorsDealroom-flagged across the org

4 AI specialistsincl. 3 core researchers

1,175 employees mappedperson by person

DimensionScore

AI Talentlive

Engineering

Product

Go-to-market

Leadership

Research

Book a demo to unlock Madrigal Pharmaceuticals's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$25M patent portfolio · 42 active families

Estimated portfolio value

$25M

0.24% of market cap · 5.4× smaller than top peer Deciphera Pharmaceuticals ($135M)

42 active patent families

Where Madrigal Pharmaceuticals innovates AmideArylCancerDiseaseImmune disorder

Where Madrigal Pharmaceuticals concentrates vs peers

Each axis is a top-10 topic across Madrigal Pharmaceuticals and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Madrigal Pharmaceuticals

An AI-synthesized read of the highest-engagement posts about Madrigal Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Madrigal Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles